This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Gablofen

Mallinckrodt plc

Drug Names(s): baclofen

Description: Gablofen is a intrathecal drug approved for the site-specific use in the management of severe spasticity.

Deal Structure: Mallinckrodt and CNS
In September 2012, Mallinckrodt, the Pharmaceuticals business of Covidien, announced a definitive agreement to acquire CNS Therapeutics. Mallinckrodt will acquire all of the outstanding capital stock of CNS Therapeutics for approximately $100 million. The transaction, subject to customary closing conditions, is expected to be completed during the fourth calendar quarter of 2012. Once the transaction has been completed, Covidien will report the CNS Therapeutics business in the Specialty Pharmaceuticals product line within the Pharmaceuticals segment. Assuming a fourth calendar quarter 2012 closing, Covidien does not expect this transaction to have a material impact on its fiscal 2013 sales or earnings per share. In October 2012, Mallinckrodt completed its acquisition of CNS.


Gablofen News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug